Table 1.
Characteristics of hepatocellular carcinoma patients and univariate assessment of long-term survival after liver transplantation n (%)
| Variables | Value | P value |
| Age (yr) | 47.99 ± 9.09 | < 0.001 |
| Gender | 0.048 | |
| Male | 204 (91.5) | |
| Female | 19 (8.5) | |
| Blood type | 0.951 | |
| A | 66 (29.6) | |
| B | 62 (27.8) | |
| O | 75 (33.6) | |
| AB | 20 (9.0) | |
| Identical | 195 (87.4) | 0.492 |
| History | ||
| Cardiovascular disease | 17 (7.6) | 0.358 |
| Respiratory disease | 3 (1.3) | 0.296 |
| Diabetes mellitus | 17 (7.6) | 0.736 |
| Hepatitis B virus infection | 223 (100.0) | 0.252 |
| Ascites | 144 (64.6) | 0.426 |
| Variceal bleeding | 25 (11.2) | 0.023 |
| Encephalopathy | 4 (1.8) | 0.799 |
| Treatment related to hepatocellular carcinoma | ||
| Hepatectomy | 21 (9.4) | 0.693 |
| Transplantation | 4 (1.8) | < 0.001 |
| TACE | 44 (19.7) | 0.756 |
| Criteria | ||
| Milan | < 0.001 | |
| Met | 88 (39.5) | |
| Exceeded | 135 (60.5) | |
| UCSF | < 0.001 | |
| Met | 97 (43.5) | |
| Exceeded | 126 (56.5) | |
| Shanghai Fudan | < 0.001 | |
| Met | 116 (52.0) | |
| Exceeded | 107 (48.0) | |
| Hangzhou | < 0.001 | |
| Met | 144 (64.6) | |
| Exceeded | 79 (35.4) | |
| MELD score | 14.12 ± 7.02 | 0.086 |
| SCr (μmol/L) | 71.41 ± 69.10 | 0.173 |
| TB (μmol/L) | 89.45 ± 174.19 | < 0.001 |
| INR | 1.42 ± 0.45 | 0.010 |
| AFP (ng/mL) | 5694.77 ± 12584.00 | < 0.001 |
| Cold ischemia time (h) | 9.21 ± 2.07 | 0.129 |
| Intraoperative blood loss (IU) | 9.24 ± 8.50 | 0.002 |
| Operation duration (h) | 8.29 ± 1.58 | 0.200 |
| Liver transplantation technique | 0.001 | |
| Classic | 212 (95.1) | |
| Piggyback | 11 (4.9) | |
| Biliary reconstruction | < 0.001 | |
| Duct-to-duct | 221 (99.1) | |
| Roux-en-Y | 2 (0.9) | |
| Edmondson grading | 0.790 | |
| I | 8 (3.6) | |
| II | 200 (89.7) | |
| III | 13 (5.8) | |
| IV | 2 (0.9) | |
MELD: Model for end-stage liver disease; SCr: Serum creatinine; TB: Total bilirubin; INR: International normalized ratio; AFP: Alfa-fetoprotein; UCSF: University of California San Francisco; TACE: Transcatheter arterial chemoembolization.